Speeding: a review of self-reported effects of amphetamine-type stimulants (ATS)

References

• Aarons GA, Brown SA, Stice E, Coe MT. 2001. Psychometric evaluation of the marijuana and stimulant effect expectancy questionnaires for adolescents. Addict Behav. 26(2):219–236.
   PubMed Web of Science ®Google Scholar
• Bahnsen P, Jacobsen E, Thesleff H. 1938. The subjective effect of beta‐phenyliso‐propylaminsulfate on normal adults. J Internal Med. 97(1–2):89–131.
   Google Scholar
• Bellis MA, Hughes K, Calafat A, Juan M, Ramon A, Rodriguez JA, Mendes F, Schnitzer S, Phillips-Howard P. 2008. Sexual uses of alcohol and drugs and the associated health risks: a cross sectional study of young people in nine European cities. BMC Public Health. 8(1):155
   PubMed Web of Science ®Google Scholar
• Brunt TM, Koeter MW, Niesink RJM, van den Brink W. 2012. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology. 220(4):751–762.
   PubMed Web of Science ®Google Scholar
• Cameron JS, Specht PG, Wendt GR. 1965. Effects of amphetamines on moods, emotions, and motivations. J Psychol. 61(1):93–121.
   PubMed Web of Science ®Google Scholar
• Cohen RS. 1995. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Progr Neuro-Psychopharmacol Biol Psychiatry. 19(7):1137–1145.
   PubMed Web of Science ®Google Scholar
• Cruickshank CC, Dyer KR. 2009. A review of the clinical pharmacology of methamphetamine. Addiction. 104(7):1085–1099.
   PubMed Web of Science ®Google Scholar
• Davison D, Parrott AC. 1997. Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol. 12(3):221–226.
   Web of Science ®Google Scholar
• de Almeida SP, Silva MTA. 2003. Ecstasy (MDMA): effects and patterns of use reported by users in Sao Paulo. Revista Brasileira de Psiquiatria. 25(1):11–17.
   PubMedGoogle Scholar
• De la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J. 2004. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 26(2):137–144.
   PubMed Web of Science ®Google Scholar
• Ferestad J, Thompson M. 2017. I’m not gonna be like ‘that guy’”: examining antidrug shock advertising through the eyes of "that guy". Deviant Behav. 38(2):173–187.
   Web of Science ®Google Scholar
• Foltin RW, Fischman MW. 1991. Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend. 28(1):3–48.
   PubMed Web of Science ®Google Scholar
• Greer G, Tolbert R. 1986. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 18(4):319–327.
   PubMed Web of Science ®Google Scholar
• Gullo MJ, Matveeva M, Feeney GF, Young RM, Connor JP. 2017. Social cognitive predictors of treatment outcome in cannabis dependence. Drug Alcohol Depend. 170:74–81.
   PubMed Web of Science ®Google Scholar
• Haertzen CA, Hill HE, Belleville RE. 1963. Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs. Psychopharmacologia. 4(3):155–166.
   PubMed Web of Science ®Google Scholar
• Hall W, Hando J, Darke S, Ross J. 1996. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction. 91(1):81–88.
   PubMed Web of Science ®Google Scholar
• Han DD, Gu HH. 2006. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 6(1):6.
   PubMedGoogle Scholar
• Hansen C. 2008. Development of a Methamphetamine Expectancies Scale. Vermillion: University of South Dakota.
   Google Scholar
• Hayaki J, Anderson BJ, Stein MD. 2008. Drug use expectancies among nonabstinent community cocaine users. Drug Alcohol Depen. 94(1–3):109–115.
   PubMed Web of Science ®Google Scholar
• Iversen L. 2008. Speed, ecstasy, ritalin: the science of amphetamines. London, UK: Oxford University Press.
   Google Scholar
• Jones L, Reed P, Parrott AC. 2016. Mephedrone and 3,4-methylenedioxy-methamphetamine: comparative psychobiological effects as reported by recreational polydrug users. J Psychopharmacol. 30(12):1313–1320.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick M, de Wit H. 2015. MDMA: a social drug in a social context. Psychopharmacology. 232(6):1155–1163.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick M, Goldenson NI, Kapadia N, Kahler CW, De Wit H, Swift RM, McGeary JE, Sussman S, Leventhal AM. 2016. Emotional traits predict individual differences in amphetamine-induced positive mood in healthy volunteers. Psychopharmacology. 233(1):89–97.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick M, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL. 2012. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans [FX]. Psychopharmacology. 219(1):109–122.
   PubMed Web of Science ®Google Scholar
• Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. 2008. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol. 28(4):432–440.
   PubMed Web of Science ®Google Scholar
• Kroutil LA, Vorburger M, Aldworth J, Colliver JD. 2010. Estimated drug use based on direct questioning and open‐ended questions: responses in the 2006 National Survey on Drug Use and Health. Int J Meth Psych Res. 19(2):74–87.
   PubMed Web of Science ®Google Scholar
• Lasagna L, von Felsinger JM, Beecher HK. 1955. Drug-induced mood changes in man: 1. Observations on healthy subjects, chronically ill patients, and postaddicts. J Am Med Assoc. 157(12):1006–1020.
   PubMed Web of Science ®Google Scholar
• Leslie EM, Smirnov A, Cherney A, Wells H, Legosz M, Kemp R, Najman JM. 2017. Simultaneous use of alcohol with methamphetamine but not ecstasy linked with aggression among young adult stimulant users. Addict Behav. 70:27–34.
   PubMed Web of Science ®Google Scholar
• Leyton M, Vezina P. 2013. Striatal ups and downs: their roles in vulnerability to addictions in humans. Neurosci BioBehav R. 37(9):1999–2014.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Gamma A, Vollenweider FX. 2001. Gender differences in the subjective effects of MDMA. Psychopharmacology. 154(2):161–168.
   PubMed Web of Science ®Google Scholar
• Liester MB, Grob CS, Bravo GL, Walsh RN. 1992. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis. 180(6):345–352.
   PubMed Web of Science ®Google Scholar
• Looby A, Earleywine M. 2010. Psychometric evaluation of a Prescription Stimulant Expectancy Questionnaire. Exp Clin Psychopharm. 18(4):375–383.
   PubMed Web of Science ®Google Scholar
• Marsh W, Copes H, Linnemann T. 2017. Creating visual differences: methamphetamine users perceptions of anti-meth campaigns. Int J Drug Policy. 39:52–61.
   PubMed Web of Science ®Google Scholar
• McKetin R, Hickey K, Devlin K, Lawrence K. 2010. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev. 29(4):358–363.
   PubMed Web of Science ®Google Scholar
• McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. 2013. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiat. 70(3):319–324.
   PubMed Web of Science ®Google Scholar
• Monson E, Lonergan M, Caron J, Brunet A. 2016. Assessing trauma and posttraumatic stress disorder: Single, open-ended question versus list-based inventory. Psychol Assess. 28(8):1001–1008.
   PubMed Web of Science ®Google Scholar
• Morefield KM, Keane M, Felgate P, White JM, Irvine RJ. 2011. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction. 106(7):1293–1300.
   PubMed Web of Science ®Google Scholar
• Nathanson MH. 1937. The central action of beta-aminopropylbenzene(benzedrine). Clinical observations. JAMA. 108(7):528–631.
   Google Scholar
• Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, Barr AM. 2013. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 129(3):167–179.
   PubMed Web of Science ®Google Scholar
• Parrott AC, Downey LA, Roberts CA, Montgomery C, Bruno R, Fox HC. 2017. Recreational 3,4-methylenedioxymethamphetamine or 'ecstasy': current perspective and future research prospects. J Psychopharmacol (Oxford). 31(8):959–966. English.
   PubMed Web of Science ®Google Scholar
• Peroutka SJ, Newman H, Harris H. 1988. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1(4):273–277.
   PubMed Web of Science ®Google Scholar
• Proudfoot P, Heubeck B, Ward J, Degenhardt L. 2011. Ecstasy use, outcome expectancies, and sexual risk taking. Aust Psychol. 46(4):219–228.
   Web of Science ®Google Scholar
• R Core Team. 2013. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing.
   Google Scholar
• Siliquini R, Faggiano F, Geninatti S, Versino E, Mitola B, Ippolito R. 2001. Patterns of drug use among young men in Piedmont (Italy). Drug Alcohol Depend. 64(3):329–335.
   PubMed Web of Science ®Google Scholar
• Solowij N, Hall W, Lee N. 1992. Recreational MDMA use in Sydney: a profile of ‘ecstasy’users and their experiences with the drug. Br J Addict. 87(8):1161–1172.
   PubMedGoogle Scholar
• Teixeira-Gomes A, Costa VM, Feio-Azevedo R, de Lourdes Bastos M, Carvalho F, Capela JP. 2015. The neurotoxicity of amphetamines during the adolescent period. Int J Dev Neurosci. 41:44–62.
   PubMed Web of Science ®Google Scholar
• The Joanna Briggs Institute. 2017. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist for Prevalence Studies. Retreived November 15, 2018 from http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Prevalence_Studies2017.pdf.
   Google Scholar
• The United Nations Office on Drugs and Crime. 2018. World Drug Report 2018. Global Overview of Drug Demand and Supply. Latest trends, cross-cutting issues.
   Google Scholar
• Thurn D, Kuntsche E, Weber JA, Wolstein J. 2017. Development and Validation of the amphetamine-Type stimulants Motive Questionnaire in a clinical Population. Front Psychiat. 8:183.
   PubMed Web of Science ®Google Scholar
• Topp L, Hando J, Dillon P, Roche A, Solowij N. 1999. Ecstasy use in Australia: patterns of use and associated harm. Drug and Alcohol Dependence. 55(1–2):105–115.
   PubMed Web of Science ®Google Scholar
• Topp L, Lovibond PF, Mattick RP. 1995. The nature of the amphetamine dependence syndrome: appetitive or aversive motivation? Sydney (Australia): National Drug & Alcohol Research Centre.
   Google Scholar
• Verheyden SL, Henry JA, Curran HV. 2003. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol. 18(7):507–517.
   PubMed Web of Science ®Google Scholar
• White TL. 2017. Beyond sensation seeking: a conceptual framework for individual differences in psychostimulant drug effects in healthy humans. Curr Opin Behav Sci. 13:63–70.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2017. Amphetamine-type stimulants. Retrieved November 27, 2017 from http://www.who.int/substance_abuse/publications/en/.
   Google Scholar
• Zervogiannis F, Bester G, Wiechers E. 2003. The “E” in rave: a profile of young ecstasy (MDMA) users. S AFR J Psychol. 33(3):162–169.
   Web of Science ®Google Scholar